Targeting apoptosis of vascular smooth muscle cells (VSMCs) represents an attractive approach to diminish the occurrence of restenosis. Neddylation is a highly conserved post-translational modification process and inhibition of neddylation has been shown to regulate apoptosis of other cells. However, the impacts of neddylation inhibition on VSMCs and neointimal hyperplasia have not been studied. In our present study, we have shown that MLN4924, a selective inhibitor of NEDD8-activating enzyme (NAE), markedly inhibited neointimal hyperplasia and accumulation of VSMCs, whereas increased apoptosis in the vascular wall. In vitro studies revealed that MLN4924 induced G2/M arrest and apoptosis of human VSMCs. Knockdown of NAE1 had similar effects. MLN4924 upregulated p53 and p62 in human VSMCs. Knockdown of either p53 or p62 mitigated the impacts of MLN4924 on G2/M arrest and apoptosis. Moreover, p53 knockdown abolished MLN4924-induced upregulation of p62. Finally, smooth muscle p53 knockout mice were generated and subjected to femoral artery injury and MLN4924 treatment. Deficiency of p53 in smooth muscle blocked the effects of MLN4924 on neointimal hyperplasia and apoptosis. Together, our results revealed that neddylation inhibition induces apoptosis through p53 and p62 in VSMCs and improves neointimal hyperplasia mainly by promoting apoptosis through smooth muscle p53 in mice. These pre-clinical data provide strong translational implications for targeting restenosis by perturbation of neddylation using MLN4924.
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Percutaneous coronary intervention (PCI) is widely used to treat coronary heart disease. 1, 2 However, the procedure itself causes vascular injury that may lead to restenosis, a major limitation of this therapeutic approach. 3 Proliferation and migration of vascular smooth muscle cells (VSMCs) have been considered two of the most important characteristics in the process of restenosis. 4, 5 However, even though the use of paclitaxel and rapamycin, both of which inhibit the proliferation and migration of VSMCs and significantly lowers the incidence of restenosis, 6 ,7 the rate of restenosis remains above 12%. 8, 9 Therefore, new strategies are still in need to achieve better outcomes.
Targeting VSMC apoptosis may be a feasible strategy to further diminish the occurrence of restenosis. It has been recognized that besides proliferation and migration, apoptosis of VSMCs also has important roles in restenosis. 10 For example, an early study has shown that overexpression of fas ligand induces apoptosis of VSMCs and inhibits neointimal hyperplasia in balloon-injured rat carotid arteries. 11 Later efforts have demonstrated that agents such as statins promote apoptosis of VSMCs and inhibit neointimal hyperplasia in animal models and are generally considered beneficial for restenosis in human patients after PCI, although clinical data are not always consistent. 12 Recent data have revealed that VSMCs are resistant to apoptosis during the development of neointimal hyperplasia and that alleviation of such resistance is highly effective in facilitation of VSMC apoptosis and reduction of neointima formation. 13 These studies have suggested that induction of VSMC apoptosis is of therapeutic interests for treating restenosis.
Neddylation, a post-translational protein modification that adds neural precursor cell expressed developmentally downregulated protein 8 (Nedd8) to target proteins, has been demonstrated to exert critical functions in cell proliferation, growth, senescence, autophagy, and apoptosis. 14, 15 Similar to ubiquitin, Nedd8 is conjugated to its substrates through an enzymatic cascade that consists of an E1-activating enzyme, an E2 conjugating enzyme, and an E3 ligase. 16 Substrates of neddylation include cullin family proteins and transcription factors such as p53, p73, and E2F1. 14, 17 Studies have shown that MLN4924, an inhibitor of Nedd8-activating enzyme (NAE), 18, 19 strikingly suppresses the growth of tumor cells through inducing senescence, autophagy, and/or apoptosis. [20] [21] [22] We therefore hypothesize that interfering neddylation may improve neointimal hyperplasia by inhibiting the growth of VSMCs.
To test the hypothesis, we first used a classical femoral wire injury mouse model that simulated the pathological changes after PCI to investigate whether MLN4924 improved neointimal hyperplasia and its effects on apoptosis of VSMCs. Then, we studied the cellular mechanisms by evaluating the impacts of MLN4924 and knockdown of NAE subunit 1 (NAE1) on cell cycle and apoptosis of human smooth muscle cells (hSMCs). Finally, we further explored the intrinsic molecular mechanisms that mediated the effects of MLN4924 in vitro and in vivo.
Results
MLN4924 inhibits arterial injury-induced neointimal hyperplasia in mice. In a wire injury mouse model, MLN4924 significantly decreased intima area and intima/ media ratio of injured femoral arteries compared with vehicle control (HPBCD) (Figures 1a and b) . Further, smooth muscle actin (SMA)-positive cells were reduced in injured femoral arteries of MLN4924-treated mice (Figures 1c and d) , indicating less accumulation of VSMCs. Apoptosis is a major factor that determines the amount of VSMCs in the neointima after vascular injury. TdT-mediated dUTP nick end labeling (TUNEL)-positive cells were significantly increased in the arteries of MLN4924-treated mice (Figures 1e and f) , whereas SMA and Ki67 double-positive cells did not differ between the two groups (Supplementary Figure S1) , suggesting that MLN4924 mainly increased apoptosis of VSMCs. The two groups showed comparable body weights (Supplementary Figure S2) . These results suggested that MLN4924 inhibited neointimal hyperplasia by promoting apoptosis of VSMCs.
MLN4924 and NAE1 knockdown both induce G2/M arrest and apoptosis in hSMCs. We then studied the impacts of MLN4924 on the growth of hSMCs to better understand the cellular and molecular mechanisms. Fluorescence-activated cell sorting (FACS) analysis showed that hSMCs in G2/M phase peaked at 24 h after DMSO treatment (Figures 2a and  b) , likely reflecting the peak of proliferation and consistent with previous observations. 23 The hSMCs in G2/M phase were markedly increased by MLN4924 treatment, particularly at 48 h and 72 h time points (Figures 2a and b) . Cyclin B1-cdc2 is a pair of key regulators that promote G2/M phase and phosphorylation of cdc2 leads to its inhibition. 24 Consistently, the protein level of cyclin B1 was decreased and that of phosphorylated cdc2 (p-cdc2) was increased by MLN4924 treatment (Figures 2c and d) . These data demonstrated that MLN4924-induced G2/M arrest in hSMCs.
TUNEL-positive cells were significantly increased by MLN4924 in hSMCs (Figures 2e and f) . Expression of cleaved caspase 3 was also upregulated by MLN4924 (Figures 2g  and h ), further suggesting that MLN4924-induced apoptosis in hSMCs. The effectiveness of MLN4924 was confirmed by the profoundly suppressed protein level of Nedd8-conjugated p53 mediates the effects of MLN4924 on G2/M arrest and apoptosis in VSMCs. MLN4924 induces apoptosis of tumor cells through DNA re-replication and damage. 25 We therefore tested whether DNA damage and checkpoint activation occurred in hSMCs treated with MLN4924. Figure S4) , suggesting that MLN4924-induced DNA damage was at least in part because of a reduction in neddylation. Furthermore, treatment of MLN4924 notably increased protein expression of chromatin licensing and DNA replication factor 1 (Cdt1) in hSMCs (Supplementary Figure S5) . Cdt1 is a known CRL substrate and its overexpression has been shown to induce DNA damage response. 26, 27 Interestingly, knockdown of Cdt1 inhibited MLN4924-induced upregulation of p-H2AX, p53, and cleaved caspase 3 in hSMCs (Supplementary Figure S6) , indicating that Cdt1 at least partially mediated the impacts of MLN4924 on DNA damage response, p53 induction, and apoptosis of these cells.
Previous studies have demonstrated that p53 has crucial roles in regulating G2/M arrest and apoptosis. 28 We then explored whether p53 mediated these effects of MLN4924 in hSMCs. siRNA-mediated knockdown of p53 (Figures 4c and  d ) markedly attenuated MLN4924-induced increase of hSMCs in G2/M phase (Figures 4e and f) , supporting that p53 mediated the effects of MLN4924 on G2/M arrest. TUNELpositive cells were also significantly decreased by p53 knockdown in MLN4924-treated hSMCs (Figures 4g and h) , suggesting that p53 mediated the effects of MLN4924 on apoptosis. Moreover, the upregulation of p53 target genes such as fas and p21, both of which were closely related to apoptosis and growth arrest, was blocked by p53 siRNA (Figure 4i ). Under the treatment of MLN4924, the protein level of cleaved caspase 3 was drastically lower in primary VSMCs from p53 KO mice compared with those from control mice (Supplementary Figure S7) , further suggesting that p53 mediated the effects of MLN4924 on apoptosis of VSMCs.
These results together demonstrated that MLN4924 induced G2/M arrest and apoptosis through p53 in VSMCs.
p62 mediates the effects of MLN4924 on apoptosis in VSMCs. MLN4924 induces autophagy in multiple cancer cell lines. 20, 22, 29 During autophagy, microtubule-associated protein 1 light chain 3-I (LC3-I) is converted to lipidated LC3-II. 30 Western blotting analysis showed that the conversion of LC3-I to LC3-II was not increased, suggesting that MLN4924 did not induce autophagy in hSMCs (Supplementary Figure S8) . Accumulation of p62 (or sequestosome 1, SQSTM1) is an indicator of suppressed autophagy. 30 Both mRNA and protein levels of p62 were upregulated by MLN4924 treatment, further indicating that MLN4924 did not increase autophagy in hSMCs (Figures 5a-c) . Studies have shown that p62 also mediates the activation of apoptosis. 31, 32 siRNA-mediated knockdown of p62 (Figure 5d ) significantly decreased the number of TUNEL-positive cells in MLN4924-treated hSMCs (Figures 5e and f) . Consistently, expression of cleaved caspase 3 was markedly decreased by p62 knockdown, further implying that p62 mediated MLN4924-induced apoptosis of hSMCs (Figures 5g and h) . However, knockdown of p62 did not affect MLN4924-induced G2/M arrest of hSMCs (Supplementary Figure S9) . At baseline without MLN4924 treatment, p62 knockdown did not affect apoptosis of hSMCs (Supplementary Figure S10) . These data indicated that p62 mediated the pro-apoptotic effects of MLN4924 without affecting G2/M arrest in hSMCs.
Notably, p53 knockdown by siRNA blocked MLN4924-induced upregulation of p62 (Figures 5i-k) , suggesting that p53 mediated the impacts of MLN4924 on p62 in regulating apoptosis of hSMCs. Moreover, knockdown of p62 in addition to that of p53 did not show further inhibition on MLN4924-induced expression of cleaved caspase 3 compared with p53 knockdown alone (Supplementary Figure S11) , implying that the impacts of p62 on MLN4924-induced apoptosis of hSMCs were completely dependent on p53. However, chromatin immunoprecipitation (ChIP) assays did not show any interaction between p53 protein and p62 promoter (Supplementary Figure S12) , suggesting that p62 was not a target gene of p53.
p53 deficiency in SMCs blocks the inhibitory effects of MLN4924 on neointimal hyperplasia in mice. Finally, we addressed the question whether p53 in SMCs mediated the effects of MLN4924 in vivo. We established an inducible smooth muscle p53 knockout (SM-p53KO) mouse model. QRT-PCR results demonstrated significant decrease of p53 gene expression in aortas of these mice compared with littermate control (LC) mice after injection of tamoxifen (Figure 6a ). LC and SM-p53KO mice were then subjected to femoral artery wire injury and treatment with MLN4924 or vehicle control. MLN4924 reduced intima/media ratio of injured femoral arteries compared with vehicle control in LC mice (Figures 6b and c) . However, this reduction was blocked in SM-p53KO mice and as a result the intima/media ratio of MLN4924-treated SM-p53KO mice was significantly higher than that of MLN4924-treated LC mice (Figures 6b and c) . Consistently, the inhibitory impact of MLN4924 on SMApositive cells in the injured arteries was blocked by SMp53KO (Figures 6d and e) . TUNEL-positive cells were significantly increased by MLN4924 and this was also blocked by SM-p53KO (Figures 6f and g ). These results together suggested that MLN4924 inhibited neointimal hyperplasia and promoted apoptosis of VSMCs through p53 in vivo.
Discussion
Clinical practice demands novel strategies to further reduce the incidence of restenosis and therefore to achieve better outcomes after PCI. Here in this study, we showed that inhibition of protein neddylation by MLN4924 was able to suppress neointimal hyperplasia in a mouse model of vascular injury. At the cellular and molecular level, inhibition of neddylation induced G2/M arrest and apoptosis of VSMCs depending on p53 and/or p62, reflecting the effects of MLN4924 in vivo.
Our data demonstrated neddylation as a potential novel therapeutic target for restenosis after PCI. Drug-eluting stents that effectively suppress proliferation of VSMCs have markedly decreased the rate of stenosis. 33, 34 However, residual risk remains and new strategies utilizing new mechanisms are warranted. Targeting apoptosis of VSMCs represents an attractive approach. In the process of restenosis, proliferation and apoptosis are two parallel events that determine the net accumulation of VSMCs in the neointima. 10 We revealed that inhibition of neddylation by MLN4924 effectively suppressed neointimal hyperplasia most likely through promoting apoptosis of VSMCs in a classical mouse model of vascular injury. These observations in mice were further elaborated by the in vitro data showing that inhibition of neddylation caused G2/ M arrest and apoptosis of VSMCs. Therefore, targeting apoptosis of VSMCs through inhibition of neddylation may be a feasible strategy to further combat restenosis. It is worth to point out that the mechanism perturbing neddylation has been tested for cancer treatment and MLN4924 is already in clinical trials, 35 which may expedite the application of the same mechanism in treating restenosis.
Mechanistically, p53 mediated the effects of MLN4924 on G2/M arrest and apoptosis of VSMCs as well as on neointimal hyperplasia in mice. We found that MLN4924 caused upregulation of both total and phosphorylation level of p53, as well as its transcriptional activity in VSMCs, likely through induction of DNA damage response. However, the mRNA level of p53 was not affected, suggesting that the regulation on p53 was at post-transcriptional level. Previous studies have demonstrated that DNA damage activates p53 by modifications including phosphorylation, 36 leading to its accumulation and increase of transcriptional activation of pro-apoptotic factors such as fas, Puma, and Bax, 37 as well as cell cycle regulation-related proteins such as p21. 38, 39 Our results unveiled similar mechanisms in VSMCs. Overexpression of p53 reduces and conversely deficiency of p53 aggravates neointima formation in mice. [40] [41] [42] Our study further demonstrated that MLN4924 improved neointimal hyperplasia depending on p53-mediated apoptosis in SMCs. It has been well documented that p53 is critical player in both G1/S arrest and G2/M arrest. 43 However, in VSMCs upregulation of p53 has been reported to induce G2/M arrest in 2 days while induce G1/S arrest only after a much longer time (5 days). 44 Similarly, our results demonstrated that upregulation of p53 by MLN4924 mainly caused G2/M arrest in VSMCs within 3 days.
There are both similarities and difference between the mechanisms of MLN4924 in VSMCs and cancer cells. Previous mechanistic studies have revealed that MLN4924 suppresses the growth of cancer cells through inactivation of Cullin-RING ligase (CRL) and subsequently inducing accumulation of CRL substrates such as Cdt1 and origin recognition complex subunit 1, both of which trigger DNA replication stress and induce DNA damage response. 45, 46 In addition, accumulation of other CRL substrates, including p21, 45 NOXA, 47 and activating transcription factor 4, 48 has been identified to mediate cell cycle arrest and/or apoptosis and to inhibit the growth of cancer cells. Similarly, our data suggested that MLN4924 induced DNA damage response, cell cycle arrest, and apoptosis in VSMCs. However, a key difference exists between the mechanisms in VSMCs vs. cancer cells. In cancer cells, p53 deficiency does not inhibit MLN4924-induced apoptosis; instead, p53-deficient cancer cells are more susceptible to the drug. 46 Our study revealed that p53 deficiency attenuated MLN4924-induced apoptosis and G2/M arrest in VSMCs, as well as blocked MLN4924-induced suppression of neointimal hyperplasia in mice.
This study also found that p62 mediated the effects of MLN4924 on apoptosis of VSMCs in vitro. MLN4924 increased the expression of p62, which mediated the effects of MLN4924 on apoptosis. Previous studies have demonstrated that deficiency of p62 aggravates neointima formation in mice, indicating an important role of p62 in neointimal hyperplasia. 49 Results in cancer cells have shown that MLN4924 causes accumulation of DEP domain containing MTOR interacting protein and hypoxia inducible factor 1 alpha that are in turn responsible for MLN4924-induced autophagy via inhibiting mTORC1. 29 Our study did not find MLN4924 induce autophagy in VSMCs. Instead, MLN4924 increased the level of p62 mRNA likely through transcriptional regulation. Similar regulation of p62 at transcriptional level has been reported before. 50 Interestingly, we demonstrated that the induction of p62 by MLN4924 was dependent on p53 in VSMCs, a novel mechanism that also mediated MLN4924-induced apoptosis. However, it remains to be further interrogated how p53 controls p62 expression in MLN4924-treated VSMCs and whether MLN4924 improves neointimal hyperplasia depending on p62 in vivo.
In conclusion, we have demonstrated that inhibition of neddylation induces VSMC apoptosis through p53/p62 and improves neointimal hyperplasia after mechanical vascular injury through p53 in mice. These findings support that regulation of neddylation is an attractive therapeutic approach to treat restenosis. Translational indications of these preclinical evidence support that MLN4924, an inhibitor of neddylation that has been tested for cancer therapy, is a strong candidate for novel treatments to further decrease the rate of restenosis after PCI. Femoral artery wire injury model. Femoral artery wire injury was performed according to methods previously described. 53 In brief, mice were anesthetized with isoflurane and a 0.38 mm flexible angioplasty guide wire (Cook Inc, Bloomington, IN, USA) was inserted rotationally into the arterial lumen of right femoral arteries and then pulled back for a total of three times. After the third insertion the guide wire was left in place for 2 min. Sham surgeries were performed on the left femoral arteries of the same mice. After 4 weeks, femoral arteries were Histology and morphometric analysis. Cross-sections of femoral arteries were stained with hematoxylin and eosin. Intimal area and medial area were measured using Image J software (National Institutes of Health, Bethesda, MD, USA). The intima to media ratio was calculated.
Cell culture. hSMCs were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA). The cells were maintained in DMEM-F12 (Thermo Scientific, Grand Island, NY, USA) supplemented with 10% FBS (Thermo Scientific), 100 U/ml penicillin, and 100 μg/ml streptomycin. hSMCs were treated with 1 μM MLN4924 or DMSO for indicated length of time before various analysis.
Primary VSMCs were isolated from aortas of 8-week-old SM-p53KO and LC mice by enzyme digestion method. 54 In brief, both thoracic and abdominal aortas were dissected from mice. Adventitia and endothelium were both removed. The samples were then cut into small pieces and digested with collagenase and elastase for 1 h. The digestion was stopped with cultured media and cells were collected and cultured in DMEM-F12 supplemented with 20% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.
293FT cells (ATCC) were cultured with DMEM (Thermo Scientific) containing 10% FBS, 100 U/ml penicillin, and 100 μg/ml streptomycin.
Immunofluorescence staining. Paraffin sections were deparaffinized, rehydrated, and subject to antigen retrieval. The sections were then blocked in 5% normal goat serum in PBS/Triton (0.3% Triton X-100 in PBS) at room temperature for 60 min and incubated with primary antibodies at 4°C overnight. On the next day, the samples were incubated with fluorochrome-conjugated secondary antibodies (1:500, Thermo Scientific) for 1 h at 37°C. Nuclei were stained by DAPI contained in mounting media (Thermo Scientific). hSMCs were seeded on coverslips and fixed with 4% paraformaldehyde at room temperature for 15 min. The samples were then blocked in serum and incubated with primary antibodies and secondary antibodies sequentially. Fluorescent signals were captured using a confocal microscope. Primary antibodies for immunofluorescence were used at the following dilutions: anti-α-SMA (Abcam, Cambridge, MA, USA) and anti-Ki67 (Cell Signaling Technology, Danvers, MA, USA).
TUNEL assay. For paraffin sections, TUNEL staining was done according to the manufacturer's protocol of In Situ Cell Death Detection Kit-TMR red (12156792910, Roche Diagnostics, Indianapolis, IN, USA). For cells, hSMCs were seeded on coverslips that were further used for TUNEL staining according to the manufacturer's protocol. Fluorescent signals were captured using a confocal microscope.
PI staining and FACS analysis. hSMCs were harvested using 0.25% trypsin, centrifuged, washed in PBS, and then fixed in 70% ethanol at − 80°C overnight. The cells were subsequently stained with propidium iodide (PI) (P4864, Sigma-Aldrich) solution containing 0.05 mg/ml PI, 0.1% Triton x-100, and 0.1 mg/ml ribonuclease A in PBS for 15 min at room temperature in dark. Cell cycle distribution was determined by Quanta SC (Beckman, Fullerton, CA, USA). Data were analyzed with Flow Jo software.
Quantitative RT-PCR. Total RNA from cells was extracted using TRIZOL (Thermo Scientific) and cDNA synthesis was accomplished using reverse transcription kits (Takara, Shiga, Japan) according to the manufacturer's protocol. Quantitative PCR was performed using SYBR Green Mix (Thermo Scientific) on an ABI7900HI (Applied Biosystems, Bartlesville, Oklahoma). Relative expression was determined via the Ct method and normalized to GAPDH as an internal control. Primer sequences were listed in Supplementary Table 1.
Total protein extraction and western blotting analysis. Cells were lysed with lysis buffer containing protease inhibitors. After quantification protein samples were separated by 10 or 15% SDS-PAGE, transferred to PVDF membranes (Millipore, Darmstadt, Germany), and analyzed by immunoblotting. The western blotting results were quantified using Image J software.
Primary antibodies were used at the following dilutions: GAPDH (1:10000, KangChen Bio-tech, Shanghai, China), Nedd8 (1:1000, Cell Signaling Technology), cyclin b1 (1:1000, Santa Cruz, Dallas, TX, USA), p-cdc2 (1:1000, Santa Cruz), cleaved caspase 3 (1:500, Cell Signaling Technology), α-tubulin (1:1000, Sigma),
